

Thalidomide-O-amido-PEG4-C2-NH2 Biochemical

Thalidomide-O-amido-PEG4-C2-NH2

CATALOG #
AAA228013


PRODUCT SYNONYMS

Thalidomide-O-amido-PEG4-C2-NH2; RAD1901 S enantiomer; Thalidomide-O-amido-PEG4-C2-NH2 biochemical


PRODUCT SPECIFICATIONS

Purity/Purification	98%
CAS	1957236-22-4
Solubility	<1mg/ml refers to the product slightly soluble or insoluble
In vitro	PROTACs contain two different ligands connected by a linker; one is a ligand for an E3 ubiquitin ligase and the other is for the target protein. PROTACs exploit the intracellular ubiquitin-proteasome system to selectively degrade target proteins[2].
Preparation and Storage	Powder: -20 degree C for 3 years In solvent: -80 degree C for 2 years

IMAGES



Structure
Elacestrant (S enantiomer), CAS 2309762-29-4



Structure
Elacestrant (S enantiomer), CAS 2309762-29-4

ADDITIONAL INFORMATION

Related Product Information for Thalidomide-O-amido-PEG4-C2-NH2 biochemical	Thalidomide-O-amido-PEG4-C2-NH2 is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker used in PROTAC technology.
References	1. Garner F, et al. RAD1901: a novel, orally bioavailable selective estrogen receptor degrader that demonstrates antitumor activity in breast cancer xenograft models. Anticancer Drugs. 2015 Oct;26(9):948-56.

For Research Use Only. Not for use in diagnostic or therapeutic procedures. Small volumes of product may become entrapped in the seal of the vial during shipment and storage; if necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the cap.